Humacyte is a company headquartered in the United States.
Humacyte develops bioengineered, off-the-shelf human acellular vessels (HAVs) for use as implantable blood vessels to treat vascular disease and provide durable vascular access for dialysis and other indications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.